|

Luspatercept Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: ACE 536, ACE-536, ACE536, Luspatercept-aamt, Reblozyl

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • National Cancer Institute (NCI)1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Celgene1

Indications

  • Cancer3
  • Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis1
  • Beta-thalassemia1
  • Acute Myeloid Leukemia, Myelodysplasia-Related1
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm1

Birmingham, Alabama1 trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Los Angeles, California1 trial

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Childrens Hospital Los Angeles RHU

Phase 3

Tampa, Florida1 trial

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Moffitt Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.